OSCR · Oscar Health, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.65B | - | $2.99B | $2.86B | $3.05B | - | $2.42B | $2.22B | $2.14B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $706.23M | - | $521.59M | $534.49M | $482.76M | - | $460.38M | $337.24M | $394.16M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $7.02M | - | - | - | $6.73M | - | - | - | $7.81M | - |
| Operating Income | $704.09M | - | ($129.25M) | ($230.48M) | $297.12M | - | ($48.37M) | $67.81M | $185.56M | - |
| Interest Expense | $5.38M | - | $6.86M | $5.85M | $5.90M | - | $5.82M | $5.99M | $5.90M | - |
| Income Tax | $19.75M | - | ($1.81M) | ($5.04M) | $12.71M | - | $2.08M | $4.64M | $996.0K | - |
| Net Income | $679.00M | - | ($137.45M) | ($228.36M) | $275.27M | - | ($54.60M) | $56.21M | $177.37M | - |
| EPS - Basic | $2.28 | - | ($0.53) | ($0.89) | $1.10 | - | ($0.22) | $0.24 | $0.77 | - |
| EPS - Diluted | $2.07 | - | ($0.53) | ($0.89) | $0.92 | - | ($0.22) | $0.20 | $0.62 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.81B | $2.77B | $2.15B | $2.60B | $2.24B | $1.53B | $1.21B | $2.27B | $2.23B | $1.87B |
| Accounts Receivable | $587.02M | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $7.78B | $4.61B | $3.76B | $4.31B | $3.77B | $2.85B | $2.37B | $3.36B | $3.50B | $3.06B |
| Total Assets | $9.29B | $6.33B | $5.75B | $6.38B | $5.84B | $4.84B | $4.48B | $5.01B | $4.42B | $3.60B |
| Current Liabilities | $7.14B | $4.86B | $3.98B | $4.87B | $4.15B | $3.46B | $2.95B | $3.50B | $3.02B | $2.43B |
| Long-term Debt | $430.88M | $430.10M | $686.29M | $299.94M | $299.75M | $299.56M | $299.36M | $299.17M | $298.97M | $298.78M |
| Total Liabilities | $7.62B | $5.34B | $4.72B | $5.22B | $4.51B | $3.82B | $3.32B | $3.87B | $3.38B | $2.80B |
| Stockholders' Equity | $1.66B | $977.65M | $1.02B | $1.16B | $1.33B | $1.01B | $1.16B | $1.14B | $1.03B | $803.97M |
| Retained Earnings | ($2.62B) | ($3.29B) | ($2.94B) | ($2.80B) | ($2.58B) | ($2.85B) | ($2.70B) | ($2.64B) | ($2.70B) | ($2.88B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.62B | - | - | - | $878.54M | - | - | - | $634.36M | - |
| Investing Cash Flow | ($590.25M) | - | - | - | ($174.23M) | - | - | - | ($300.59M) | - |
| Financing Cash Flow | ($3.60M) | - | - | - | $4.87M | - | - | - | $27.31M | - |
| CapEx | $8.79M | - | - | - | $9.03M | - | - | - | $5.95M | - |
| Free Cash Flow | $2.61B | - | - | - | $869.52M | - | - | - | $628.41M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 15.2% | - | -4.3% | -8.0% | 9.8% | - | -2.0% | 3.1% | 8.7% | - |
| EBITDA margin | 15.3% | - | - | - | 10.0% | - | - | - | 9.0% | - |
| Net margin | 14.6% | - | -4.6% | -8.0% | 9.0% | - | -2.3% | 2.5% | 8.3% | - |
| Free cash flow margin | 56.2% | - | - | - | 28.5% | - | - | - | 29.3% | - |
| FCF / Net income | 3.84 | - | - | - | 3.16 | - | - | - | 3.54 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 15.2% | - | 17.5% | 18.7% | 15.8% | - | 19.0% | 15.2% | 18.4% | - |
| Effective tax rate | 2.8% | - | - | - | 4.4% | - | - | 7.6% | 0.6% | - |
| Return on assets | 7.3% | - | -2.4% | -3.6% | 4.7% | - | -1.2% | 1.1% | 4.0% | - |
| Return on equity | 40.8% | - | -13.4% | -19.7% | 20.6% | - | -4.7% | 4.9% | 17.2% | - |
| Return on invested capital | 32.7% | - | -6.0% | -12.5% | 17.4% | - | -2.6% | 4.4% | 13.9% | - |
| Liquidity | ||||||||||
| Current ratio | 1.09 | 0.95 | 0.95 | 0.89 | 0.91 | 0.82 | 0.80 | 0.96 | 1.16 | 1.26 |
| Quick ratio | 1.09 | 0.95 | 0.95 | 0.89 | 0.91 | 0.82 | 0.80 | 0.96 | 1.16 | 1.26 |
| Cash ratio | 0.67 | 0.57 | 0.54 | 0.53 | 0.54 | 0.44 | 0.41 | 0.65 | 0.74 | 0.77 |
| Leverage | ||||||||||
| Debt / Equity | 0.26 | 0.44 | 0.67 | 0.26 | 0.22 | 0.30 | 0.26 | 0.26 | 0.29 | 0.37 |
| Debt / Assets | 0.05 | 0.07 | 0.12 | 0.05 | 0.05 | 0.06 | 0.07 | 0.06 | 0.07 | 0.08 |
| Debt / EBITDA | 0.61 | - | - | - | 0.99 | - | - | - | 1.55 | - |
| Interest coverage | 130.8x | - | -18.8x | -39.4x | 50.3x | - | -8.3x | 11.3x | 31.4x | - |
| Equity multiplier | 5.58 | 6.47 | 5.61 | 5.51 | 4.38 | 4.78 | 3.86 | 4.40 | 4.28 | 4.48 |
| Liabilities / Assets | 0.82 | 0.84 | 0.82 | 0.82 | 0.77 | 0.79 | 0.74 | 0.77 | 0.77 | 0.78 |
| Efficiency | ||||||||||
| Asset turnover | 0.50 | - | 0.52 | 0.45 | 0.52 | - | 0.54 | 0.44 | 0.48 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 46d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 5.5x | - | - | - | 14.2x | - | - | 79.1x | 24.0x | - |
| P / B | 2.3x | - | 4.8x | 4.7x | 3.0x | - | 4.4x | 4.2x | 4.2x | - |
| P / S | 0.8x | - | 1.6x | 1.9x | 1.3x | - | 2.1x | 2.2x | 2.0x | - |
| EV / EBITDA | -0.8x | - | - | - | 6.8x | - | - | - | 12.6x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 52.6% | - | 23.2% | 29.0% | 42.2% | - | 68.3% | 45.9% | 45.8% | - |
| Revenue CAGR (3y) | 46.8% | - | 45.1% | 41.2% | 46.3% | - | 187.8% | - | 164.8% | - |
| Revenue CAGR (5y) | 109.4% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 137.0% | - | -167.2% | - | 60.1% | - | 16.9% | - | - | - |
| Net income growth (YoY) | 146.7% | - | -151.8% | - | 55.2% | - | 16.5% | - | - | - |
| EPS growth (YoY) | 125.0% | - | -140.9% | - | 48.4% | - | 24.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 200.2% | - | - | - | 38.4% | - | - | - | 54.3% | - |
| FCF CAGR (5y) | 91.1% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 24.8% | -3.5% | -11.9% | 1.8% | 29.2% | 26.1% | 26.5% | 19.8% | 11.0% | -9.7% |
Peer comparison
Same SIC group: Hospital & Medical Service Plans
Comparing Oscar Health against the 5 most active filers in the same SIC group.